Read the latest news from Northwestern University Feinberg School of Medicine’s Parkinson's Disease and Movement Disorders Center. The links below take you to articles where you can learn more about our faculty’s latest achievements, awards, and honors.
Northwestern Medicine scientists have shed light on a hallmark of Parkinson’s disease that has been poorly understood up until now, the buildup of a protein called α-synuclein in the brain.
A clinical study led by Northwestern Medicine scientist Tanya Simuni, MD, has crossed a promising compound off the list of potential agents that may slow the progression of Parkinson’s disease.
In an international study, Northwestern Medicine scientists and colleagues have identified a novel strategy for reducing the side effects of uncontrolled movement caused by the drug levodopa, commonly used to treat the stiffness, tremors and poor muscle control of Parkinson’s disease
- Advisory Council Grant for Junior Investigators08.17.2015
For the 2016 initiative, the Parkinson's Disease and Movement Disorders Advisory Council will award two grants of $25,000 to junior investigators. Please see the request for proposal document for more information.
Submissions are due by Friday, October 30, 2015, by 5 p.m. For additional information please contact Trupti Patel at 312-503-3320.
A futility analysis find pioglitazone won't help slow disease progression
- 06.21.2015A multidisciplinary Huntington’s Disease clinic, part of the Parkinson’s Disease and Movement Disorders Center at Feinberg, launched this spring to be that one-stop shop, a place where patients can receive comprehensive care to manage their symptoms and improve their quality of life.
More people are making big health decisions based on genetic tests
Clinic will provide patients collaborative treatments and the latest research for one of the most devastating genetic neurological disorders
- 05.03.2014Center study featured in the Chicago Sun Times for May 3, 2014.
- 04.02.2014Tanya Simuni, MD, medical director of Northwestern University’s Parkinson’s Disease and Movement Disorders Center, was awarded a grant from the National Institutes of Health (NIH) to conduct a $16 million phase III study of the safety and efficacy of the drug isradipine as a potential neuroprotective agent in Parkinson’s disease.
Recognized for its approach to uncovering new therapeutic targets in the fight against Parkinson’s disease (PD), Northwestern University Feinberg School of Medicine will continue that pursuit as a National Institutes of Health Center of Excellence. The only medical school to receive new or renewed designation as a Morris K. Udall Center of Excellence for Parkinson’s Disease Research in 2013, Feinberg became the Midwest’s first site in 2003, and today is one of just 10 nationwide.